Panitumumab-Induced Periorbital Dermatitis: A Case Report
Issued Date
2024-01-01
Resource Type
eISSN
11787015
Scopus ID
2-s2.0-85190797202
Journal Title
Clinical, Cosmetic and Investigational Dermatology
Volume
17
Start Page
763
End Page
767
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical, Cosmetic and Investigational Dermatology Vol.17 (2024) , 763-767
Suggested Citation
Pongbangpho N., Chanprapaph K., Iamsumang W. Panitumumab-Induced Periorbital Dermatitis: A Case Report. Clinical, Cosmetic and Investigational Dermatology Vol.17 (2024) , 763-767. 767. doi:10.2147/CCID.S459067 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/98166
Title
Panitumumab-Induced Periorbital Dermatitis: A Case Report
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Panitumumab is a recombinant, fully humanized immunoglobulin G2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is approved for the first-and second-line treatment of advanced wild-type KRAS colorectal cancer. Although common cutaneous side effects include acneiform dermatitis, folliculitis, and xerosis, ocular toxicities have occasionally been reported. Herein, we report the case of an 81-year-old Thai female with chemorefractory advanced stage sigmoid colon cancer who developed isolated periorbital dermatitis following treatment with panitumumab plus modified FOLFOX6. The cutaneous adverse reaction recurred after subsequent infusions; however, it was alleviated by topical therapy. To our knowledge, panitumumab-induced periorbital dermatitis is exceptionally rare. To raise awareness of potential periocular cutaneous side effects in patients taking EGFR inhibitors, the published literature regarding periorbital dermatitis induced by these agents has also been reviewed in this article. Periorbital dermatitis should be considered as a potential cutaneous reaction following panitumumab administration, and should be promptly treated.